key: cord-0950542-n32u8hzk authors: Mentzer, Dr Alexander J; James, Tim; Yongya, Mirak; Cox, Stuart; Paddon, Kevin; Shine, Brian; Bowen, Jordan; Novak, Alex; Knight, Julian C; Fullerton, James N title: Serum calprotectin is not an independent predictor of severe COVID-19 in ambulatory adult patients date: 2021-11-27 journal: J Infect DOI: 10.1016/j.jinf.2021.11.017 sha: ff8683e7cceb07f6c9c550f6e9051314ad36a39b doc_id: 950542 cord_uid: n32u8hzk nan Dear Editor, Whilst COVID-19 represents a self-limiting disease in most patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a small proportion of individuals may develop life threatening respiratory and multi-organ failure associated with prolonged hospital admission and intensive care stay 1 . In the United Kingdom (UK), same-day emergency care (SDEC) units operating an ambulatory-care-by-default model review a high volume of patients at risk of developing severe disease where rapid decisions must be made regarding treatment and the setting of care delivery, predominantly based on prediction of risk of deterioration 1 . To support attending clinicians models incorporating age, comorbidities, clinical metrics and blood test results (particularly C-reactive protein) have been established that estimate the risk of adverse clinical outcomes, encompassing the need for intensive care unit (ICU) admission, non-invasive ventilation (NIV), or death 2,3 . Calprotectin is a cytosolic protein with pro-inflammatory signalling properties released by activated neutrophils. Both an elevated circulating calprotectin concentration and excessive neutrophil degranulation have been mechanistically associated with severe COVID-19 disease 4, 5 . Recent studies, including two published in this journal, have subsequently proposed serum calprotectin as an early sensitive biomarker for predicting deterioration from COVID-19 in Emergency Departments (ED) [6] [7] [8] . Whether the utility of serum calprotectin extends to adult patients attending SDEC, and whether its addition to existing deterioration models improves prediction of deterioration is unknown. To determine this, from February to April 2021 we prospectively asked SDEC clinicians in Oxford University NHS Foundation Trust, UK, to order a pre-specified panel of biochemical blood tests through an electronic 'Careset' (EPR, Cerner Millenium) for all patients suspected of having COVID-19 based on symptomology or epidemiology. Selection of the Careset triggered automatic analysis of serum calprotectin using a particle enhanced turbidimetric assay (Gentian AS, Moss, Norway). Clinicians were blinded to calprotectin results, and laboratory staff blinded to COVID-19 status. We Testing correlation between measured biomarkers in the full dataset of 771 individuals, the highest correlation was observed between neutrophil count and calprotectin (rho=0.61) with a similar estimate observed between calprotectin and CRP (rho=0.58; Figure 1B) . In multivariate models, when used alongside CRP with age and sex, calprotectin led to only a marginal improvement in predicative capability. There was no incremental benefit when using all available data as part of a gold standard predictive model (Supplementary Table 1 ). We conclude that in this large cohort attending SDEC during a surge of COVID-19 in the UK, whilst serum calprotectin was found to be a potential predictor of deterioration, there was little evidence that it offered benefit over and above existing biomarkers including peripheral cell counts or CRP. Other studies investigating calprotectin as a potential predictor of adverse outcome include a German ED study that enrolled 66 individuals with suspected COVID-19 where calprotectin was found to have a AUROC of 0.87, compared to 0.70 for CRP, for predicting multi-organ failure within 72 hours 6 . Another Spanish ED study found estimates of 0.80 and 0.79 respectively for predicting death during admission 7 . Thus, these reported estimates for CRP are similar to ours whereas our estimate for calprotectin is significantly lower. This discrepancy could be due to the timing of sampling in relationship to clinical deterioration 4 . Equally, as neither calprotectin nor neutrophil count were associated with risk of deterioration in our SDEC cohort there is the possibility that calprotectin may be more helpful in patients presenting more unwell to ED. Although we were unable to collect some important variables such as duration of symptoms and standardised radiology results owing to the priority of anonymization, our double-blind prospective design using standardised clinical data available through electronic healthcare records with multivariable analyses reduces the risk of selection bias and offers an effective, pragmatic opportunity for the rapid assessment of other such biomarkers in the future. Our findings do not support the widespread uptake of serum calprotectin use in ambulatory adult patients to predict COVID-19 deterioration, but does support the ongoing use of biomarkers such as CRP alongside standard clinical assessment in this setting as well as for predicting deterioration from other respiratory disease in SDEC. Biomarkers to predict the risk of deterioration of patients presenting to ambulatory care with COVID-19. A) The receiver operating curve (ROC) distributions for three biomarkers associated with deterioration measured in 222 individuals with confirmed COVID-19. ROC analyses were undertaken using the pROC package and the comparison of the paired ROC statistics was calculated using DeLong's test 10 . B) The Spearman rank rho correlation between the log 10 -transformed distributions of the predominant biomarkers associated with disease severity and deterioration in COVID-19 studies to date as measured in 771 individuals presenting to ambulatory care with symptoms consistent with COVID-19. Clinical Characteristics of Coronavirus Disease 2019 in China Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Development and validation of the 4C Mortality Score Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19 Correspondence Fuping You. Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19 Outcome prediction by serum calprotectin in patients with COVID-19 in the emergency department Circulating levels of GDF-15 and calprotectin for prediction of inhospital mortality in COVID-19 patients: A case series Circulating Calprotectin as a Biomarker of COVID-19 Severity Trends over time in Escherichia coli bloodstream infections, urinary tract infections, and antibiotic susceptibilities in pROC: An open-source package for R and S+ to analyze and compare ROC curves We thank the clinicians and other allied health staff contributing to this study. This Reagents for serum calprotectin measures were provided by Gentian AS. Gentian AS had no role in the design, performance or analysis of the study but reviewed the results and interpretation before presentation. All authors declare no conflicts of interest.Glasgow coma scale